Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 52Other hematologic neoplasm 8Dermatologic 8Thoracic 3Gastrointestinal 2Breast 2Plasma cell 1Head & Neck 1

Conditions

Breast Neoplasms 166Triple Negative Breast Neoplasms 54Neoplasm Metastasis 23Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 11Colorectal Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Lung Neoplasms 8Prostatic Neoplasms 7Colonic Neoplasms 7Breast Neoplasms, Male 7Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 3Rectal Neoplasms 3Multiple Myeloma 3Melanoma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2

Interventions

Therapeutics 6Cyclophosphamide 6Flow Cytometry 5Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Filgrastim 4pembrolizumab 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Nivolumab 3Immunoenzyme Techniques 3Blood Specimen Collection 3sargramostim 2liposomal amphotericin B 2durvalumab 2copanlisib 2belinostat 2aldesleukin 2Vorinostat 2Surveys and Questionnaires 2Stem Cell Factor 2Rituximab 2Ondansetron 2Methylprednisolone 2Melphalan 2Itraconazole 2Ipilimumab 2Immunologic Techniques 2Gemcitabine 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hodgkin Disease × Gemcitabine × Breast × Clear all
NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Mayo Clinic

Phase 1 Terminated
17 enrolled
BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Incyte Corporation

Phase 1 Terminated
5 enrolled
BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡